Deliverables list

D Deliverable name WP No. Lead beneficiary Dissemination level Delivery date
D1.1 Establishment of a Steering Committee 1 1 PU 1
D1.2 Establishment of a Management Office 1 1 PU 1
D1.3 Kick off meeting 1 1 PU 1
D1.4 Signed consortium agreement 1 1 PU 3
D1.5 Project presentation produced 1 1 PU 3
D1.6 Establishment of a Scientific Advisory
Group
1 1 PU 6
D1.7 Establishment of a webpage with
password-protected info
1 1 PU 6
D1.8 Establishment of Technology Transfer
Work Group
1 1 PU 6
D1.9 Establishment of Ethical Review Work
Group.
1 1 PU 6
D1.10 Annual Report #1, reviews from the
Technological Transfer Work and
Ethical Review Work groups..
1 1 PU 12
D1.11 Annual meeting of the General
Assembly
1 1 PU 18
D1.12 Update of Annex I according to State-of-
the-art
1 1 PU 24
D1.13 Report from the meeting of the Scientific
Advisory Board.
1 1 PU 26
D1.14 Annual Report #2, reviews from the
Technological Transfer Work and
Ethical Review Work groups..
1 1 PU 26
D1.15 Annual meeting of the General
Assembly
1 1 PU 30
D1.16 Annual Report #3 reviews from the
Technological Transfer Work and
Ethical Review Work groups..
1 1 PU 38
D1.17 Report from the meeting of the Scientific
Advisory Board.
1 1 PU 38
D1.18 Annual meeting of the General
Assembly
1 1 PU 40
D1.19 Final Report, reviews from the
Technological Transfer Work and
Ethical Review Work groups..
1 1 PU 48
WP No. Lead beneficiary Dissemination level Delivery date
D2.1 Construction of central databases for
each cancer to hold individual
phenotype and SNP data from the
GWAS to be used in stage I
2 2 PP 3
D2.2 Integration of SNP data from GWAS
into the SNP database
2 2 PP 6
D2.3 Complete analysis of existing GWA data
for breast , ovarian and prostate cancer
– novel loci identified to be followed up
by WP4/5/6/7
2 2 PP 9
D2.4 Define set of SNPs for breast, ovarian
and prostate cancer, for genotyping in
phase II (WP3)
2 2 PP 12
D2.5 Incorporate individual SNP genotype
data generated in stage II (WP3, task
3.2) into the central databases
2 2 PP 21
D2.6 First reports describing main effect
association analyses for each cancer
2 2 PP 24
D2.7 Define set of SNPs to be typed for each
cancer in WP3
2 2 PP 24
D2.8 Integration of gene expression data for
breast cancer into the gene expression
database.
2 2 PU 24
D2.9 Website giving access to combined
analyses
2 2 PP 24
D2.10 Incorporate data from WP3 into
database
2 2 PU 33
D2.11 Report describing main effect
association analyses for subtypes (with
WP7)
2 2 PP 39
D2.12 Reports on final main effects analysis
for each cancer
2 2 PP 42
D2.13 Report on main effects of SNPs in
BRCA1/2 carriers
2 2 PP 42
D2.14 Reports describing gene-gene
interaction analyses in each cancer
2 2 PP 45
D2.15 Report of risk models for breast and
ovarian cancer
2 2 PP 45
D2.16 Report of risk model for prostate cancer 2 2 PU 45
D2.17 Report describing mapping of
expression subtypes to
histopathological equivalents for breast
cancer
2 2 PU 45
D2.18 Website for the risk models for
estimating the risk of breast, ovarian
and prostate cancer.
2 2 PU 45
No. Deliverable name WP No. Lead beneficiary Dissemination level Delivery date
D3.1 Samples shipment to CNIO from other
groups
3 3 PP 9
D3.2 Samples preparation for shipping and
genotyping
3 3 PP 12
D3.3 Design and synthesis of Illumina
Custom Arrays
3 3 PP 14
D3.4 Generation of genotypes (stage II) of
the three diseases (50,000 samples)
3 3 PP 22
D3.5 Evaluation of assays for
Taqman/iPlex/Veracode
3 3 PP 28
D3.6 Data replication and generation of
genotypes (stage III)
3 3 PP 33
WP No. Lead beneficiary Dissemination level Delivery date
D4.1 Manuscript describing the fine-scale
mapping process and results in one
breast cancer locus
4 2 6
D4.2 Report describing initial loci submitted
for fine-scale mapping
4 2 PP 12
D4.3 Website cataloguing the candidate
causative variants at each locus,
identified by WP4 Task 1
4 2 PU 24
D4.4 Report describing any additional loci.
identified as suitable for fine-scale
mapping if costs permit, from the
confirmed loci listed in D2.7
4 2 PP 30
D4.5 Update of D4.3 4 2 PU 36
D4.6 Report presenting the list of candidate
cancer-causing mutations defined by
WP4 Task 2 and listing planned papers
4 2 PP 48
WP No. Lead beneficiary Dissemination level Delivery date
D5.1 Questionnaires from consortia members
collected and posted on COGS website
5 4 PP 3
D5.2 Data dictionary of established and
suspected lifestyle/environmental risk
factors for each cancer site, including
variable definition and coding, finalized
and placed on COGS website
5 4 PP 6
D5.3 A database with harmonized
epidemiologic data established for each
of the different cancers and for
BRCA1/2 mutation carriers
5 4 PP 12
D5.4 Results posted on the COGS website
from analysis of gene and environment
(GxE) performed for the already
established susceptibility loci of breast
cancer
5 4 PP 18
D5.5 List of selected lifestyle/environmental
variables used for exploratory analysis
of GxE analyses for breast cancer with
all 1536 SNPs genotyped to be placed
on COGS website
5 4 PP 23
D5.6 Results posted on the COGS website
from analysis of GxE performed for the
possible susceptibility loci of breast
cancer from previous GWAS
5 4 PP 26
D5.7 Results posted on the COGS website
from analysis of GxE (using global
variables) performed for breast cancer
in BRCA1/2 mutation carriers and for
the established susceptibility loci from
GWAS for ovarian and prostate cancer
5 4 PP 28
D5.8 List of selected detailed variables for
GxE analyses in breast, ovarian and
prostate cancer to be placed on COGS
website
5 4 PP 30
D5.9 Results posted on the COGS website
from analysis of GxE analysis for
confirmed susceptibility loci for breast,
ovarian, and prostate cancer
5 4 PP 40
WP No. Lead beneficiary Dissemination level Delivery date
D6.1 Standardization of histopathological and
immunohisto data; codebook
6 9 PP 8
D6.2 TMA scoring system for the different
immuno-histochemical analyses agreed
6 9 PP 12
D6.3 Database for the incorporation of the
histopathological and
immunohistopathology data established
6 9 PP 12
D6.4 Draft of two manuscript based on pre-
COGS data, i.e. tumour subtype
survival analyses, and genotype and
tumour subtype risk analyses.
6 9 PP 16
D6.5 Existing data on tumour characteristics
coded and incorporated in developed
database
6 9 PP 16
D6.6 The SNP data from Stage I of
genotyping from WP3 will be added to
the database including tumour
characteristics
6 9 PP 18
D6.7 Standard risk and prognosis analyses
will be performed using genotype (G)
and tumour type (T)(standard
histopathology)
6 9 PP 24
D6.8 Analyses of genotype/environment
interaction (GxE) and (T) will be
performed
6 9 PP 24
D6.9 Draft manuscript deliverable 6.6 6 9 PP 26
D6.10 New G data WP3/WP4 added to
database
6 9 PP 28
D6.11 New G and T(standard histopathology)
analysis
6 9 PP 30
D6.12 New GxE and T(standard
histopathology) analysis
6 9 PP 33
D6.13 Draft manuscripts deliverable
6.7/6.10/6.11
6 9 PP 33
D6.14 Coding of available TMA staining in
developed database
6 9 PP 36
D6.15 Standard risk and prognosis analyses
will be performed using genotype (G)
and tumour type (T)(using TMA)
6 9 PP 38
D6.16 Standard risk and prognosis analyses
will be performed using genotype (G)
and tumour type (T)(using CGH)
6 9 PP 40
D6.17 Initial analysis GxE and T (TMA) 6 9 PP 38
D6.18 Initial analysis GxE and T(expression or
CGH-array)
6 9 PP 38
D6.19 New refined G & E data WP3/4/5 added
to database
6 9 PP 42
D6.20 Draft manuscripts deliverable 6.14-16 6 9 PP 42
WP No. Lead beneficiary Dissemination level Delivery date
D7.1 Participant list and report of first
Steering Group meeting
7 10 PP 3
D7.2 Draft terms of reference and agreed
participant list for main Working Group
7 10 PP 9
D7.3 International Working Group Workshop
1 (programme/participants)
7 10 PP 15
D7.4 First draft paper on risk stratification
using polygenic model
7 10 PP 18
D7.5 Workshop 1 report outlining key issues
in targeted prevention
7 10 PU 21
D7.6 Scientific paper on risk stratification
assuming a polygenic inheritance model
7 10 PU 24
D7.7 First draft report on effectiveness/cost-
effectiveness of targeted screening
7 10 PP 24
D7.8 Final report on effectiveness/ cost-
effectiveness of targeted screening
7 10 PP 27
D7.9 International Working Group Workshop
2 (programme/participants)
7 10 PP 30
D7.10 Workshop 2 report 7 10 PU 36
D7.11 International Working Group Workshop
3 (programme/participants)
7 10 PP 42
D7.12 Workshop 3 report 7 10 PP 45
WP No. Lead beneficiary Dissemination level Delivery date

Additional information